Celiac Disease Treatment Market Growth, Size, Trends Analysis - By Treatment, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Celiac Disease Treatment Market Introduction and Overview

According to SPER market research, 'Global Celiac Disease Treatment Market Size- By Treatment, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Celiac Disease Treatment Market is predicted to reach 2044.24 million by 2034 with a CAGR of 12.9%.

Celiac disease symptoms can be effectively managed and prevented by adhering to a strict, lifelong gluten-free diet. Gluten, which is found in wheat, barley, and rye, causes inflammation and poor nutrient absorption by attacking the lining of the small intestine. By removing gluten from their diet, people can reduce inflammation and heal their digestive systems. Moreover, patients often need supplements to correct vitamin and mineral deficiencies caused by malabsorption, making nutritional therapy crucial.

Restraints: The growth of the worldwide market for therapies for celiac disease is hampered by several factors. One of the biggest challenges is that there is currently no cure for celiac disease; those who have it must live their entire lives on a gluten-free diet, which can be expensive and challenging to maintain. Additionally, celiac disease can be challenging to identify because its symptoms often resemble those of other conditions, delaying a definitive diagnosis. Early detection and treatment are therefore crucial but challenging.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment, By Route of Administration, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Amgen Inc., Amneal Pharmaceuticals LLC, BioLineRx Ltd., Glenmark Life Sciences Limited, Hikma Pharmaceuticals PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Tangshan UMG Medical Instrument Co., Ltd., Viatris Inc., and others.

Celiac Disease Treatment Market Segmentation:

By Treatment: Based on the Treatment, Global Celiac Disease Treatment Market is segmented as; Vitamins & Minerals, Gluten-free Diet, Medical Therapies.

By Route of Administration: Based on the Route of Administration, Global Celiac Disease Treatment Market is segmented as; Oral, Parenteral.

By Distribution Channel: Based on the Distribution Channel, Global Celiac Disease Treatment Market is segmented as; Hospitals, Research Centers, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Product Code: HLCA2534

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Celiac Disease Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Celiac Disease Treatment Market

7. Global Celiac Disease Treatment Market, By Treatment, (USD Million) 2021-2034

7.1. Vitamins & Minerals
7.2. Gluten-free Diet
7.3. Medical Therapies
- 7.3.1. Infliximab
- 7.3.2. Larazotide Acetate
- 7.3.3. Azathioprine
- 7.3.4. Budesonide
- 7.3.5. Others

8. Global Celiac Disease Treatment Market, By Route of Administration, (USD Million) 2021-2034

8.1. Oral
8.2. Parenteral

9. Global Celiac Disease Treatment Market, By Distribution Channel, (USD Million) 2021-2034

9.1. Hospitals
9.2. Research Centers
9.3. Others

10. Global Celiac Disease Treatment Market, (USD Million) 2021-2034

10.1. Global Celiac Disease Treatment Market Size and Market Share

11. Global Celiac Disease Treatment Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Amgen Inc.
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Amneal Pharmaceuticals LLC.
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. BioLineRx Ltd.
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Glenmark Life Sciences Limited
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Hikma Pharmaceuticals PLC
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Novartis AG
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Takeda Pharmaceutical Company Limited.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Teva Pharmaceutical Industries Ltd.
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Tangshan UMG Medical Instrument Co., Ltd.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Viatris Inc.
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others